Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
adapt, analyst, Attestation, Bulgaria, channel, composition, concurrently, contemplated, contrary, COSO, defend, deficient, distributor, driven, earliest, excessively, extent, familiarize, FAMP, Fanucci, follicular, front, GlaxoSmithKline, GSK, harbor, Hydra, immaterial, incorrect, indeterminate, ingredient, inInternal, input, insight, investee, Iomega, Janssen, Keating, kinase, Korea, lab, Laurie, lymph, mantle, Marsha, MCL, narrowing, NCCN, Network, NHL, Oscient, outcome, paradigm, penetration, reacquired, recourse, reevaluated, reliant, relieve, repaid, retrospective, Revlimid, RTK, Secretary, shelf, Slovenia, Society, spleen, steady, strong, Sybase, thereon, timeframe, toxin, Treadway, tyrosine, uneconomical, unexpectedly, unprecedented, unqualified, Unregistered, widespread, zone
Removed:
accelerate, age, aimed, amortizing, auditing, Biogen, biotherapeutic, bowel, choice, CMR, combine, conducting, Crohn, derived, disrupted, distributed, downstream, entity, escalating, ethical, filling, focusing, formed, founding, generating, genetic, hired, home, hope, impede, internally, international, kenneth, medicinal, murine, occupy, oral, participate, past, pivotal, population, predictive, predisposition, prone, prosecuting, recognizing, restated, retroactively, rheumatoid, selectively, seventeen, social, stroke, structured, suffering, surgery, thereof, transitional, transpire, unconsolidated, varying, weighted, workforce, Xenova, XOMA
Filing tables
Filing exhibits
Related press release
MLNM similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
STATEMENT PURSUANT TO 18 U.S.C. §1350
Pursuant to 18 U.S.C. §1350, the undersigned certifies that this Annual Report on Form 10-K for the period ended December 31, 2004 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Millennium Pharmaceuticals, Inc.
| Dated: March 8, 2005 | /s/ MARSHA H. FANUCCI Marsha H. Fanucci Senior Vice President and Chief Financial Officer (Principal financial officer) |
A signed original of this written statement required by Section 906 has been provided to Millennium Pharmaceuticals, Inc. and will be retained by Millennium Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.